323 related articles for article (PubMed ID: 26687001)
1. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages.
Tang K; Lu W; Qin W; Wu Y
Pancreatology; 2016; 16(1):28-37. PubMed ID: 26687001
[TBL] [Abstract][Full Text] [Related]
2. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.
Gillen S; Schuster T; Meyer Zum Büschenfelde C; Friess H; Kleeff J
PLoS Med; 2010 Apr; 7(4):e1000267. PubMed ID: 20422030
[TBL] [Abstract][Full Text] [Related]
3. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.
Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Aitini E; Barni S;
Pancreas; 2015 May; 44(4):515-21. PubMed ID: 25872127
[TBL] [Abstract][Full Text] [Related]
4. Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.
Huan L; Yu F; Cao D; Zhou H; Qin M; Cao Y
PLoS One; 2024; 19(3):e0295983. PubMed ID: 38451955
[TBL] [Abstract][Full Text] [Related]
5. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
6. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy.
Javed AA; Wright MJ; Siddique A; Blair AB; Ding D; Burkhart RA; Makary M; Cameron JL; Narang A; Herman J; Zheng L; Laheru D; Weiss MJ; Wolfgang C; He J
J Gastrointest Surg; 2019 Jan; 23(1):112-121. PubMed ID: 30242644
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: a meta-analytical evaluation of prospective studies.
Festa V; Andriulli A; Valvano MR; Uomo G; Perri F; Andriulli N; Corrao S; Koch M
JOP; 2013 Nov; 14(6):618-25. PubMed ID: 24216547
[TBL] [Abstract][Full Text] [Related]
8. Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2-3 studies.
Tomasello G; Ghidini M; Ghidini A; Trevisan F; Celotti A; Russo A; Gambini D; Indini A; Rijavec E; Bareggi C; Galassi B; Petrelli F
Radiother Oncol; 2021 Nov; 164():13-19. PubMed ID: 34509562
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer.
McClaine RJ; Lowy AM; Sussman JJ; Schmulewitz N; Grisell DL; Ahmad SA
HPB (Oxford); 2010 Feb; 12(1):73-9. PubMed ID: 20495649
[TBL] [Abstract][Full Text] [Related]
10. Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Janssen QP; van Dam JL; Kivits IG; Besselink MG; van Eijck CHJ; Homs MYV; Nuyttens JJME; Qi H; van Santvoort HJ; Wei AC; de Wilde RF; Wilmink JW; van Tienhoven G; Groot Koerkamp B
Ann Surg Oncol; 2021 Dec; 28(13):8297-8308. PubMed ID: 34142290
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies.
Andriulli A; Festa V; Botteri E; Valvano MR; Koch M; Bassi C; Maisonneuve P; Sebastiano PD
Ann Surg Oncol; 2012 May; 19(5):1644-62. PubMed ID: 22012027
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies.
Zhan HX; Xu JW; Wu D; Wu ZY; Wang L; Hu SY; Zhang GY
Cancer Med; 2017 Jun; 6(6):1201-1219. PubMed ID: 28544758
[TBL] [Abstract][Full Text] [Related]
14. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
[TBL] [Abstract][Full Text] [Related]
15. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
16. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer].
Scheufele F; Friess H
Chirurg; 2020 May; 91(5):391-395. PubMed ID: 31965198
[TBL] [Abstract][Full Text] [Related]
17. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma.
Brown KM; Siripurapu V; Davidson M; Cohen SJ; Konski A; Watson JC; Li T; Ciocca V; Cooper H; Hoffman JP
Am J Surg; 2008 Mar; 195(3):318-21. PubMed ID: 18308038
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
van Dam JL; Janssen QP; Besselink MG; Homs MYV; van Santvoort HC; van Tienhoven G; de Wilde RF; Wilmink JW; van Eijck CHJ; Groot Koerkamp B;
Eur J Cancer; 2022 Jan; 160():140-149. PubMed ID: 34838371
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]